A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.
Clinical Trials
FOCUS Trial of HEPZATO KIT Shows Efficacy in Metastatic Uveal Melanoma
A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.
TIL Therapy Promising in Uveal Melanoma, Tool Predicts Responders
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.
SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma